LIGHT·AI

Light AI's Healthcare Technology Featured on Beast Philanthropy

Vancouver, B.C., February 16, 2025 – Light AI Inc. ("Light AI" or the "Company") (CBOE CA: ALGO / FSE: 0HC), a global healthcare technology company focused on developing artificial intelligence health diagnostic and wellness solutions today is featured in Beast Philanthropy's latest video which has just gone live on YouTube.

The video feature marks the beginning of a new initiative that will be carried out by Light AI and MrBeast Industries in Africa. The initiative aims to address the need for better disease detection methods to specifically identify Strep A, which when left unidentified and untreated can lead to rheumatic heart disease in children and/or fatalities.

According to preliminary data from the CDC, Strep A reached an all-time high in 2023. Strep A, which is the direct cause of rheumatic heart disease, a condition commonly found in school children, has a prevalence rate of nearly 18 cases per 1000 children in East Africa, which is considerably higher than results from developed countries according to the National Institute of Health.

The company is proud to be working with MrBeast Industries in tackling this very serious, yet preventable disease, and to donate its tech-powered Strep A tests to ensure better health outcomes for several African communities.

The MrBeast video featuring Light AI's technology can be found [here](#).

About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC)

Light AI Inc. is a healthcare company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of StrepA—to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5B smartphones that exist in the world today.

In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The Company's algorithm generated pre-Federal Drug Administration (FDA) results were in the range of the "Gold Standard" swab culture currently used for diagnosing GAS achieving a 96.57% accuracy rate that is and a Negative Predictive Value (NPV) of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI's technology offers a significant

advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

"George Reznik"

George Reznik
Chief Financial Officer

For more information, please contact the Company at 604-307-6800 or visit https://light.ai/.

Investor Relations:
investors@light.ai

Media Contact:
Sarah Mawji-Walker
Venture Strategies
sarah@venturestrategies.com

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

Forward-Looking Information: